Cranberry Extract PACs Inhibit Bacterial Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Uncomplicated urinary tract infections (UTIs) are prevalent and challenging to treat due to antibiotic resistance and recurrent infections, with existing treatments often leading to resistance and recurrence issues.
Innovation Solution
A cranberry extract with a specific high degree of polymerization proanthocyanidins (PACs) is used as a single active ingredient or adjuvant to inhibit bacterial adhesion and biofilm formation in the urinary tract, effectively preventing and treating uncomplicated lower urinary tract infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat UTIs, then bacterial infections are eliminated, but antibiotic resistance develops leading to treatment failure
Solution Approach 1:
The patent uses cranberry proanthocyanidins as an intermediary substance that blocks bacterial adhesion to urinary tract epithelium. This mediator prevents UPEC from establishing infection by interfering with the bacterial adhesion mechanism, offering an alternative to antibiotics that does not select for resistance
Solution Approach 2:
The patent applies preliminary anti-action by preventing bacterial adhesion before infection can establish. Cranberry PACs are administered to block UPEC attachment to uroepithelial cells, preventing the infection process at its earliest stage rather than treating established infection
2Reliability
If conventional cranberry extracts are used, then some preventive effect is achieved, but high molecular weight PACs are not adequately absorbed
Solution Approach 1:
The patent segments the PAC mixture by separating low molecular weight (LMW) and high molecular weight (HMW) fractions, then combines them in optimized ratios. This segmentation allows each fraction to fulfill its specific role: HMW for adhesion blocking and LMW for absorption and systemic distribution
Solution Approach 2:
The patent changes the molecular weight distribution parameters of the PAC extract by controlling extraction conditions and purification steps. The extract is standardized to contain specific ranges of PAC molecular weights (LMW: 300-1000 Da, HMW: 1000-5000 Da) to optimize both absorption and efficacy
3Reliability
If cranberry extract is used to prevent UTIs, then bacterial adhesion is inhibited, but the mechanism of action with high molecular weight PACs is not fully understood
Solution Approach 1:
The patent incorporates feedback mechanisms through in vitro adhesion assays and in vivo animal models to validate the anti-adhesion activity. These feedback systems allow measurement of bacterial attachment to uroepithelial cells and confirmation that the extract effectively blocks adhesion in biologically relevant systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cranberry extract effectively reduces bacterial adhesion and biofilm formation, providing a non-resistance inducing solution for UTI prevention and treatment, as demonstrated by its ability to inhibit UPEC strains and promote intestinal barrier integrity.
Implementation Method 1
The primary condition for the onset of a UTI is the adhesion of pathogenic bacteria on the urogenital epithelial cells. The bacterial adhesion is mediated by structures of the bacterial cell surface called adhesins which allow adhesion to host cell membranes.
Implementation Method 2
UPEC strains reach the urinary tract mainly due to the anatomical continuity between perineal/perianal and vaginal areas. Therefore, UTIs originate when the uropathogenic agent residing in the intestine contaminates the periurethral area, subsequently colonizing the urethra.
Data Source
AI summary
The present invention relates to a cranberry extract in which the degree of polymerization (%m/m) in total proanthocyanidins (PACs) is between 12.5 and 15%, and in which the ratio (weight of all proanthocyanidin polymers) /(total weight of proanthocyanidins) is > 60%. This cranberry extract is used as a single active ingredient or as an adjuvant for the prevention and treatment of uncomplicated lower urinary tract infections.